(309±38 cpm). BE2 also reacted with an antigen present on EBV-B-cell lines (RIA, mean±SD = 654±194) and MOLT 3 and HUT 78 T-cell lines. BE2 reacted with an antigen expressed on a subpopulation of lymphocytes from five of eight patients with B-cell CLL studied by IIF (mean±SD = 18±6). Other long-term T-cell lines and tumor cell lines studied by IIF were unreactive with BE2. BE2 did not react with any of the normal tissues studied. BE2 precipitated a molecule (78,000 D) from CTCL cells and EBV-B cells with a single component under reducing conditions.
Immunoperoxidase-labeled BEI and BE2 reacted with CTCL cells in frozen sections of infiltrated lymph nodes and skin. In addition, BE1 and BE2 reacted with blood lymphocytes from 16 of 21 patients whose CTCL had otherwise been considered localized to skin.
These two monoclonal antibodies react with tumor antigens associated with CTCL and appear to be useful in the diagnosis of this disorder. INTRODUCTION Monoclonal antibodies with specificity for T lymphocytes at various stages of differentiation have facilitated the characterization of human lymphocyte membrane antigens. Use of these reagents have revealed that certain leukemias are neoplastic amplifications of T-cell populations with distinctive phenotypes. For example, the malignant lymphocytes of some patients with acute lymphocytic leukemia express a phenotype similar to that found on cortical thymocytes (1) . In contrast, the malignant lymphocytes from patients with cutaneous T-cell lymphoma (mycosis fungoides, Sezary syndrome) regularly have a phenotype characteristic of mature normal helper T cells (2) (3) (4) , cor- relating with prior studies which indicated that cutaneous T-cell lymphoma (CTCL)' cells frequently have the functional capabilities of helper T cells (5, 6) .
Although the linkage of helper T-cell phenotype and skin infiltration supports the suggestion that CTCL is a single entity, monoclonal antibodies specific for normal helper T cells are not helpful in distinguishing CTCL from benign helper T-cell infiltrates. CTCL, which has an incidence approximating that of Hodgkin's disease (7) , typically presents as a cutaneous disorder, subsequently disseminating widely to the viscera. The median survival from time of light microscopic diagnosis of CTCL is 5 yr (8) . Monoclonal reagents capable of identifying the skin phase of CTCL might permit diagnosis at a time when intensive therapy directed at the skin could be curative (9) .
Monoclonal antibodies against tumor-associated antigens of acute lymphoblastic and chronic myelocytic leukemia cells (10) , mammary tumors (11) , melanoma (12) , and colonic carcinoma (13) have been reported. The observation that CTCL cells could be distinguished from normal helper T cells by their failure to express the phenotypic marker 3A1 (4) raised the possibility that CTCL might also express tumor-associated antigens.
We report here the production of two monoclonal antibodies that react with human CTCL cells, but not with normal helper T cells. These reagents appear to be valuable in the diagnosis of the cutaneous lesions of CTCL, as well as in recognizing histologically inapparent extracutaneous spread by the malignant cells.
METHODS

Hybridoma production
Immunization schedule. Hybridomas were produced using modifications of the methodology defined by Kohler and Milstein (14) . BALB/c mice (West Seneca Farms, Buffalo, NY) were primed with 1 X 107 lymphocytes obtained from leukapheresis of a patient with T-cell leukemia. Previous phenotypic and functional studies revealed that the leukemic cells from this patient (M.B., lymphocyte count 420 X 106/ml) were helper T lymphocytes (98% OKTI+, 87% OKT4+, 87% OKT4+, 0% OKT5+) (2). These cells were injected intraperitoneally into mice and the mice were boosted at weekly intervals for 3 wk. Sera were obtained from the retroorbital plexus of the mice, and the antibody titers were determined before fusion.
Fusion. The splenocytes were obtained by teasing the spleens until a cell suspension was formed. The cell suspen-' Abbreviations used in this paper: CLL, chronic lymphocytic leukemia; CTCL; cutaneous T-cell lymphoma; EBV, Epstein-Barr virus; DME, Dulbecco's-modified Eagle's medium; FCS, fetal calf serum; HAT, hypoxanthine, aminopterin, thymidine; IIF, indirect immunofluorescence; PHA, phytohemagglutinin.
sion was collected and washed in Iscoves-modified Dulbecco's media (IMDM, Gibco Laboratories, Grand Island Biological Co., Grand Island, NY) containing 20% fetal calf serum (FCS, Gibco Laboratories). Each hyperimmunized mouse spleen yielded at least 2 X 108 spleen cells.
The myeloma cell line used for fusion was 45.6TG.1.7.5 (clone 5), a variant of MPC 11 which lacks the ability to produce immunoglobulin heavy chains. The myeloma cell line was deficient in the enzyme hypoxanthine guanine phosphoribosyl transferase, and therefore grown in Dulbecco'smodified Eagle's medium (DME, Gibco Laboratories) 20% FCS containing 5 usg/ml thioguanine (6 amino mercaptopurine, Sigma Chemical Co., St. Louis, MO). The myeloma and spleen cells were fused in 2 ml of 35% polyethylene glycol solution (PEG 1000, J. T. Baker Chemical Co., Phillipsburg, NJ) in DME, pH 8-8.2 (15) .
Plating. 2d before plating the fusion, the media was preconditioned by using normal BALB/c spleen cells as a feeder layer at a concentration of 1 X 105 cells/ml ( column -1 mg/ml) followed by 20 Al of rabbit anti-mouse IgG and 250 Al of IgG Sorb was used. Precipitates were washed as previously described (20) , bound materials eluted by boiling in 2% sodium dodecylsulfate (SDS) , and the immunoprecipitates analyzed using either 5% P04 or 12.5% Tris glycine polyacrylamide SDS slab gels (21) . After electrophoresis, gels were fixed and stained and the position of the bands determined by autoradiography. Kodak X-0 mat film (Eastman Kodak Co., Rochester, NY) was exposed at -70°C with an intensifying screen.
Statistical evaluation
Evaluation of the results for statistical significance was performed by use of the standard Student's t test (22 (Tables I and  II) . Increasing concentrations of the heterologous 1251. labeled rabbit anti-mouse reagent showed enhanced binding of BEI and BE2 to CTCL lymphocytes and EBV-B-cell lines. However, even 100,000 cpm of the rabbit anti-mouse antibody did not bind significantly to normal peripheral blood lymphocytes incubated with BEI or BE2 ( Table I) .
Two of these antibodies (BEI and BE2) were strongly reactive with CTCL cells and were selected for further study. The third antibody was not studied further since its reactivity with CTCL cells was relatively weak. In addition to the EBV-B-cell line, both monoclonal antibodies were tested against lymphocytes obtained from patients with B-cell chronic lymphocytic leukemia (CLL) ( Table III) . Cells from five of eight patients with B-cell CLL, evaluated by IIF, reacted with BE2 (mean = 18±6). Malignant B cells from none of these CLL patients were reactive with BEI (Table III) .
Neoplastic with leukemic and nonleukemic CTCL were studied by RIA (Table IV) . Significant binding of BEI (P . 0.001) was found in both peripheral blood and lymph node specimens from four CTCL patients. BE2 reacted with lymphocytes from one patient with leukemic disease and was also detected by RIA on lymphocytes from an effaced lymph node of one patient with nonleukemic CTCL. In addition, lymphocytic infiltrates in lymph nodes and skin biopsies from three patients with advanced CTCL reacted with BEI and BE2 in situ by the immunoperoxidase method. In Fig. la Transformed cell lines derived from T-cell leukemias and null-cell leukemias, as well as EBV-B-cell lines, were studied by both RIA and IIF to determine the distribution of the antigens recognized by BEl and BE2. EBV-transformed B-cell lines showed significant binding of BEI and BE2 (P < 0.001, Table II) as determined by RIA. MOLT 3 and HUT 78, a CTCL line, were the only tested long-term T-cell lines that reacted with BE2 while BEI reacted with HUT 78, HUT 102, and DND 1056 (Table V) . IIF studies demonstrated that BEI and BE2 do not react with JM, CM, CEM, HPB-ALL, or a null-cell all line. In addition, tumor cell lines were unreactive with BEl or BE2 (Table VI) . These negative tumor lines included a melanoma cell line propagated in nude mice, two breast cancer cell lines, a colon carcinoma cell line, and promyelocytic, myelocytic, and erythroid cell lines. Nonreactivity of BEI and BE2 with normal tissues. Frozen sections of normal tissues were screened for reactivity with BEl and BE2. As presented in Table  VII , there was no staining detected in any of the normal tissues screened.
Studies on patients with primary CTCL. Peripheral blood specimens from 21 patients with clinically evident CTCL, without histologically apparent lymph node involvement, were tested for expression of the antigens detected by BEI and BE2. 10 of these patients were studied in a double-blind fashion, and the codes were broken after completion of the study with karyotypes, and histopathology as reported in Table VIII. These CTCL patients were divided into three groups. Group I (Table VIII) (Fig. 2a ). An additional small molecular mass component of 12,000 D was also present and may represent f32-microglobulin. BE2 precipitated a molecule from both CTCL cells and EBV-B cells that has a single chain with a molecular mass of 78,000 D (Fig. 2b) .
In one case the EBV-B-cell line was precipitated with the monoclonal antibody BE2 (Fig. 2b) . Preclearing of this gel with BEI did not remove any of the antigens reactive with BE2.
DISCUSSION
CTCL is a malignancy of epidermotropic helper T cells. Early in the course of CTCL, neoplastic T cells localize in the skin and frequently form focal intraepidermal collections termed Pautrier microabscesses (9) . As the disease progresses, the predominant malignant T-cell subclones demonstrate progressively less affinity for the epidermis and a parallel propensity to disseminate to internal viscera. The loss of epidermotropism increases the difficulty of diagnosis, since the cutaneous pathology becomes less distinctive. Early diagnosis of CTCL is of great importance, since it appears that initially CTCL may be limited to the skin, and therapy aimed at that organ may be efficacious (9) . Once the malignant cells disseminate to viscera, systemic therapy is required.
Karyotypic evidence has suggested that CTCL is a monoclonally derived malignancy (25) . Those findings imply that two noncontiguous epidermal plaques must arise by hematogenous dissemination of the neoplastic (6, 26) , and chromosome breaks deletions, duplications, and rearrangements are probably late sequelae of the aberrant mitotic process in CTCL. Furthermore, the morphologic abnormalities associated with CTCL are not specific for the disorder and have been noted in normal mitogen-activated lymphocytes, as well as in benign skin infiltrates (27) .
The possibility that CTCL lymphocytes have lost normal T-lymphocyte antigens and might express an altered cell surface phenotype has been suggested by two studies. Haynes et al. (4) have shown that an antigen expressed on normal T lymphocytes, recognized by the monoclonal antibody 3A1, is generally not present on CTCL lymphocytes. Similarly, studies performed in our laboratory (2) have revealed that lymphocytes from some CTCL patients no longer carry an antigen recognized by the pan-T-cell monoclonal antibody OKT1, while still expressing a mature helper T-cell phenotype (OKT3+, OKT4+, OKT5-).
These studies have shown that at least two different tumor-associated antigens recognized by the monoclonal antibodies BEl and BE2 occur on CTCL lymphocytes. The presence of tumor-associated antigens on the surface of neoplastic cells in various leukemias (T-cell acute lymphocytic leukemia, B-cell acute lymphocytic, non-T non-B-cell acute lymphocytic leukemia, chronic myelocytic leukemia) was initially suggested by studies involving heteroantisera (28, 29) . Due to weak reactivity of heterologous antisera and the incomplete removal of nonspecific antibodies by even exhaustive absorptions with transformed cell lines, tumor-associated antigens have been difficult to isolate and characterize. The introduction of hybridoma technology for the production of monoclonal antibodies has confirmed the existence of tumor-associated antigens and allowed the detection of weakly immunogenic molecules.
The presence of tumor-related molecules on CTCL cells has been detected by two monoclonal antibodies, BEI and BE2 which identify two separate antigenic determinants. BEl has reacted with lymphocytes from the majority of CTCL patients as well as with an EBV-B-cell line. Peripheral blood lymphocytes from normal controls, and patients with benign skin disease, do not express significant quantities of BEL. Similarly, BE2 has been shown to be present on lymphocytes from some CTCL patients and on cells from transformed T-and B-cell lines. Normal lymphocytes, and benign dermatoses do not show detectable reactivity with BE2.
The antigens recognized by BEl and BE2 are clearly not restricted in expression to CTCL lymphocytes, but rather are present on a variety of transformed cell types. The absence of expression of these tumor-associated molecules on normal lymphocytes permits the The results from studies of peripheral blood specimens from patients with early CTCL suggest that BEl and BE2 may facilitate the diagnosis of this disorder. The ability to rapidly identify circulating abnormal cells in patients with disease otherwise considered limited to the epidermis would allow the earlier institution of systemic therapy.
The potential of monoclonal antibodies in the treatment of CTCL is intriguing. Previous studies using heterologous antithymocyte globulin (30) and monoclonal anti-normal T cell antibodies (31) 
